Clinical Trial Update: Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a dose-escalation study of CRLX301 in patients with advanced solid tumors has been terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor Malignancy

Drugs mentioned

• CRLX301 (CRLX301)

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Advanced Solid Tumor Malignancy | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-06-09